NEWS RELEASE 10-JUN-2024 Peer-Reviewed PublicationUNIVERSITY OF CALIFORNIA – SAN FRANCISCO FOR IMMEDIATE RELEASE Media Contact: Jess Berthold (628) 399-0432 [email protected] Subscribe to UCSF News For Type 1 Diabetes Distress, Focus First on Managing EmotionsVirtual, emotion-centered program cuts distress in half after one year, while also improving patients’ glucose control. The most effective way to reduce the...
Tag: <span>type 1 diabetes</span>
Post
Study links small pancreas size to faster progression to stage 3 type 1 diabetes
by Vanderbilt University Medical Center Graphical Abstract. Credit: Diabetes Care (2023). DOI: 10.2337/dc23-1681A multicenter, longitudinal study, co-led by investigators at the Vanderbilt Diabetes Research and Training Center (DRTC), has discovered that a small pancreas size predicts a faster progression to stage 3 type 1 diabetes (T1D), the point at which clinical diagnosis occurs. The team also...
Post
New model links RNA editing glitch to early-stage type 1 diabetes
Hebrew University of Jerusalem Hebrew University study proposes a new model suggesting that disrupted RNA editing within pancreatic beta cells might initiate an inflammatory response akin to early-stage type 1 diabetes. This new perspective challenges the long-held belief of viral involvement, offering potential implications for treatments and cures. A recent study by researchers at the...
Post
Gut microbes may determine patients’ response to a drug that delays onset of type 1 diabetes
by Delthia Ricks , Medical Xpress Teplizumab delays type 1 diabetes (T1D) in at-risk individuals in TN10 trial, but participants respond differently to the treatment. Systemic, non-pathogenic antibody responses to gut bacteria can be quantified by anti-commensal antibody (ACAb) assay. Individuals with higher IgG2 responses to specific gut bacteria are more likely to get early...
Post
World-first human trial finds arthritis drug can suppress progression of type 1 diabetes
by St Vincent’s Institute of Medical Research Credit: CC0 Public Domain Researchers at St Vincent’s Institute of Medical Research (SVI) in Melbourne have shown that a commonly prescribed rheumatoid arthritis drug can suppress the progression of type 1 diabetes. The world-first human trial, published in the New England Journal of Medicine and led by SVI’s Professor...
Post
Relieving stress in insulin-producing cells protects against type 1 diabetes
by Chris Barncard, University of Wisconsin-Madison Graphical abstract. Credit: Cell Metabolism (2023). DOI: 10.1016/j.cmet.2023.10.014 Removing a gene that manages stress within insulin-producing beta cells draws helpful attention from the immune system, protecting mice predisposed to type 1 diabetes from developing the disease, a new University of Wisconsin–Madison study shows. The study also found that changes discovered...
Post
Real-Time CGM Plus Insulin Pump Best for Type 1 Diabetes
Miriam E. Tucker Youth with type 1 diabetes who use real-time continuous glucose monitoring (rtCGM) and an insulin pump spend more time in target glucose range than those using intermittently scanned CGM (isCGM) and/or multiple daily insulin injections, new data show. In the multinational cohort study of more than 4500 people younger than age 21...
Post
Study provides preliminary evidence in favor of a new type 1 diabetes treatment
by University of Chicago Medical Center Credit: Cell Reports Medicine (2023). DOI: 10.1016/j.xcrm.2023.101261 Type 1 diabetes is an autoimmune disease that causes the body’s immune system to attack and destroy insulin-producing beta cells in the pancreas. Traditional management of type 1 diabetes has primarily involved replacing the missing insulin with injections which, though effective, can be...
Post
Verapamil can preserve beta cell function in Type 1 diabetes
by Jeff Hansen, University of Alabama at Birmingham Credit: Unsplash/CC0 Public DomainIn 2012, University of Alabama at Birmingham researcher Anath Shalev, M.D., reported that a decades-old blood pressure medication called verapamil completely reversed diabetes in animal models. In 2018, the team had translated these findings into a randomized, controlled, clinical trial, demonstrating significantly improved beta...
Post
33% of Type 1 Diabetes Patients Insulin-Free With Stem Cells
Miriam E. Tucker July 03, 2023 SAN DIEGO — An investigational allogeneic stem cell–derived pancreatic islet cell replacement therapy (VX-880, Vertex Pharmaceuticals) continues to show promise as a treatment for type 1 diabetes, according to the latest data, from six patients thus far. Two of the six are insulin-independent beyond 1 year after receiving the VX-880 infusions,...